An FDA warning letter accuses some drug manufacturers of distributing unapproved stem cell products which caused at least 12 cases of infection due to bacterial contamination.
A leading cancer researcher who failed to reveal deep industry ties and millions in payments has been ousted from a leading cancer center and sparked debate about the need for…
The FDA announced new bladder cancer restrictions on the use of Keytruda and Tecentriq, following indications that they could lower survival rates for some patients.
An FDA warning indicates that Keytruda and Tecentriq may decrease the risk of survival in certain metastatic urothelial cancer patients.
Roche has temporarily halted a clinical trial of a combination of the cancer drugs Tecentriq and Cotellic following the deaths of several patients involved in the study.
A new study raises questions about the safety and effectiveness of Taxotere, which underperformed in both survival rates and side effects when compared to Tecentriq for treatment of lung cancer.
Xolair has been approved for use in children ages six to 11, despite concerns over side effects which have led some to suggest it be removed from the market.
Health Canada has added a pancreatitis warning to the melanoma drug Zelboraf following a safety review.
The FDA is warning that the asthma drug Xolair may increase the risk of blood vessel problems in the brain and heart.
The FDA has linked the leukemia drugs Rituxan and Arzerra to reactivation of hepatitis B virus and deaths due to liver failure.
